FrancophonIA/ELRC3.0 huggingface dataset:
English: After moderate muscle relaxation, the average time for recovery was between 1.4 and 2.1 minutes for 2 mg/kg Bridion, compared with 17.6 to 18.9 minutes for neostigmine.
Estonian: Mõõduka lihaslõõgastuse järel oli lihaste normaalse talitluse keskmine taastumisaeg Bridioni 2 mg/kg annuse kasutamisel 1,4-2,1 minutit ja neostigmiini kasutamisel 17,6-18,9 minutit.
English: This was compared with spontaneous recovery after muscle relaxation using succinylcholine (another muscle relaxant).
Estonian: Seda võrreldi spontaanse taastumisega pärast suktsinüülkoliiniga (samuti müorelaksant) tekitatud lihaslõõgastust.
English: The fourth study, involving 115 patients, looked at the effectiveness of 16 mg/kg Bridion in producing rapid reversal of the muscle relaxation using rocuronium.
Estonian: Neljandas uuringus, milles osales 115 patsienti, vaadeldi 16 mg/kg Bridioni efektiivsust rokurooniumiga tekitatud lihaslõõgastuse kiirel lõpetamisel.
English: Bridion was compared with neostigmine (another medicine used to stop the effect of muscle relaxants) given after rocuronium or vecuronium in the first study and after cis-atracurium (another muscle relaxant) in the second.
Estonian: Bridioni võrreldi neostigmiiniga (samuti müorelaksantide toime peatamise ravim), mida esimeses uuringus manustati pärast rekurooniumi või vekurooniumi ja teises uuringus pärast cis-atrakuuriumi (samuti müorelaksant).
English: After deep muscle relaxation, recovery took an average of around 3.0 minutes with 4 mg/kg Bridion, compared with around 49.5 minutes for neostigmine.
Estonian: Sügava lihaslõõgastuse järel oli Bridioni 4 mg/kg annuse kasutamisel keskmine taastumisaeg ligikaudu 3,0 minutit ja neostigmiini kasutamisel ligikaudu 49,5 minutit.
English: The active substance in Bridion, sugammadex, is a ‘selective relaxant binding agent'.
Estonian: Bridioni toimeaine sugammadeks on selektiivne relaksante siduv aine.
English: The effect of Bridion seen in adults was similar in adolescents and children aged over two years.
Estonian: Noorukitel ja vähemalt 2-aastastel lastel täheldati sarnast Bridioni toimet nagu täiskasvanutel.
English: Two of the studies, involving a total of 282 patients, looked at the effectiveness of 2 mg/kg Bridion in reversing moderate relaxation of the muscles due to rocuronium or vecuronium.
Estonian: Kahes uuringus, milles osales kokku 282 patsienti, vaadeldi Bridioni 2 mg/kg annuse efektiivsust rokurooniumist või vekurooniumist tingitud mõõdukast lihaslõõgastusest taastumisel.
English: How does Bridion work?
Estonian: Kuidas Bridion toimib?
English: Bridion is not recommended for use in children and adolescents for recovery after vecuronium, or for rapid recovery after any muscle relaxant.
Estonian: Lastel ja noorukitel ei ole Bridioni soovitatav kasutada vekurooniumi toimest taastumiseks ega ühegi müorelaksandi toime kiireks lõpetamiseks.
English: When used for rapid recovery, patients receiving 16 mg/kg Bridion recovered after 4.2 minutes.
Estonian: Kiireks taastumiseks patsientidele manustatud Bridioni 16 mg/kg annuse korral oli taastumisaeg 4,2 minutit.
English: What benefit has Bridion shown during the studies?
Estonian: Milles seisneb uuringute põhjal Bridioni kasulikkus?
English: How is Bridion used?
Estonian: Kuidas Bridioni kasutatakse?
English: It is given as a single intravenous ‘bolus' injection (given into a vein all at once).
Estonian: Ravimit manustatakse ühe veenisisese boolussüstena (kogu ravim süstitakse veeni ühekorraga).
English: What is Bridion used for?
Estonian: Milleks Bridioni kasutatakse?
English: How has Bridion been studied?
Estonian: Kuidas Bridioni uuriti?
English: Bridion sugammadex
Estonian: Bridion sugammadeks
English: Bridion is used to reverse the effect of the muscle relaxants rocuronium and vecuronium.
Estonian: Bridioni kasutatakse müorelaksantide rokurooniumi ja vekurooniumi toimest taastumiseks.
English: The third study compared the effectiveness of 4 mg/kg Bridion with that of neostigmine after deep relaxation of the muscles using rocuronium or vecuronium in 182 patients.
Estonian: Kolmandas uuringus võrreldi 182 patsiendil 4 mg/kg Bridioni ja neostigmiini toimet pärast rekurooniumi või vekurooniumiga tekitatud sügavat lihaslõõgastust.
English: A dose of 16 mg/kg can be used if rapid recovery from muscle relaxation is needed.
Estonian: Kui on vaja kiiret taastumist lihaslõõgastusest, tohib kasutada annust 16 mg/kg.
English: Bridion was more effective than neostigmine in reducing the time it took for the muscles to recover, after both moderate and deep muscle relaxation using rocuronium or vecuronium.
Estonian: Bridion lühendas lihaste normaalse talitluse taastumist rokurooniumi või vekurooniumiga tekitatud mõõduka kuni sügava lihaslõõgastuse järel efektiivsemalt kui neostigmiin.
English: The medicine can only be obtained with a prescription.
Estonian: Bridion on retseptiravim.
English: Further information on Segluromet can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Seglurometi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The dose is one tablet twice a day with food.
Estonian: Annus on üks tablett kaks kord ööpäevas koos toiduga.
English: What measures are being taken to ensure the safe and effective use of Segluromet?
Estonian: Mis meetmed võetakse, et tagada Seglurometi ohutu ja efektiivne kasutamine?
English: Segluromet is available as tablets in 4 strengths of ertugliflozin and metformin (2.5 mg/850 mg, 2.5 mg/1,000 mg, 7.5 mg/850 mg and 7.5 mg/1,000 mg).
Estonian: Seglurometi turustatakse ertugliflosiini ja metformiini 4 tugevusega tablettidena (2,5 mg / 850 mg, 2,5 mg / 1000 mg, 7,5 mg / 850 mg ja 7,5 mg / 1000 mg).
English: The European Medicines Agency concluded that Segluromet's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Seglurometi kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise saab Euroopa Liidus heaks kiita.
English: Other information about Segluromet
Estonian: Muu teave Seglurometi kohta
English: What is Segluromet and what is it used for?
Estonian: Mis on Segluromet ja milleks seda kasutatakse?
English: As for all medicines, data on the use of Segluromet is continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Seglurometi kasutamise kohta pidevat järelvalvet.
English: The most common side effects with Segluromet (which may affect more than 1 in 10 people) are fungal infections of the vagina and other infections of the female reproductive system and problems with the gut such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite.
Estonian: Seglurometi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on tupe seeninfektsioonid ja naiste reproduktiivsüsteemi muud infektsioonid ning soolestiku probleemid, nagu iiveldus, oksendamine, kõhulahtisus, kõhuvalu ja isutus.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Segluromet have been included in the summary of product characteristics and the package leaflet.
Estonian: Seglurometi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Segluromet (ertugliflozin / metformin hydrochloride)
Estonian: Segluromet (ertugliflosiin/metformiinvesinikkloriid)
English: For more information about using Segluromet, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Seglurometi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: The strength of Segluromet tablet to use depends on how well the patient's glucose levels are controlled.
Estonian: Kasutatava Seglurometi tableti tugevus sõltub sellest, kui hästi patsiendi glükoosisisaldus on reguleeritud.
English: Side effects reported with Segluromet are carefully evaluated and any necessary action taken to protect patients.
Estonian: Seglurometi kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: It must also not be used in patients with severe kidney problems or certain heart, circulatory, breathing or liver problems and in patients who drink alcohol to excess.
Estonian: Ravimit ei tohi kasutada raskete neeruprobleemidega ega teatud südame-, vereringe-, hingamis- või maksaprobleemidega patsientidel ega alkoholi liigtarvitavatel patsientidel.
English: • patients who are already taking ertugliflozin and metformin as separate tablets.
Estonian: • patsiendid, kes juba võtavad ertugliflosiini ja metformiini eraldi tablettidena.
English: What are the risks associated with Segluromet?
Estonian: Mis riskid Seglurometiga kaasnevad?
English: Segluromet can also help some patients lose weight.
Estonian: Segluromet võib mõnel patsiendil aidata langetada kehakaalu.
English: Steglatro is not as effective in patients with moderate kidney impairment and should therefore not be started in such patients.
Estonian: Seglurometi ei ole mõõduka neerufunktsiooni kahjustusega patsientidel nii efektiivne, mistõttu ei tohi seda ravi nendel patsientidel alustada.
English: Studies showed that Segluromet can help lower glucose levels in patients whose metformin treatment is not working well enough, including those taking another diabetes medicine in addition to metformin.
Estonian: Uuringutes tõendati, et Segluromet aitab vähendada vere glükoosisisaldust patsientidel, kellel ainult metformiin ei toimi piisavalt hästi, sealhulgas patsientidel, kes kasutavad lisaks metformiinile mõnda muud diabeediravimit.
English: Four main studies in over 3,600 patients with type 2 diabetes have shown that adding ertugliflozin to metformin helps lower glucose levels when metformin is not working well enough.
Estonian: Neljas põhiuuringus, milles osales üle 3600 II tüüpi diabeediga patsiendi, tõendati, et ertugliflosiini lisamine metformiinile aitab vähendada vere glükoosisisaldust, kui ainult metformiinist ei piisa.
English: Segluromet must not be used in patients with uncontrolled diabetes with severe symptoms that lead to high acid levels in the blood.
Estonian: Seglurometi ei tohi kasutada reguleerimata diabeedi ja raskete sümptomitega patsientidel, sest see võib suurendada vere happesisaldust.
English: In this study, HbA1c levels fell by 0.6 points with ertugliflozin and 0.7 points with glimepiride.
Estonian: Selles uuringus vähenes HbA1c sisaldus ertugliflosiini rühmas 0,6 protsendipunkti ja glimepiriidi rühmas 0,7 protsendipunkti.
English: • patients whose glucose levels are not well controlled with the highest dose of metformin they can take
Estonian: • patsiendid, kelle glükoosisisaldus ei ole suurima neile sobiva metformiiniannusega piisavalt reguleeritud;
English: An overview of Segluromet and why it is authorised in the EU
Estonian: Ülevaade ravimist Segluromet ja ELis müügiloa väljastamise põhjendus
English: Segluromet is a medicine used to control blood glucose (sugar) levels in adults with type 2 diabetes.
Estonian: Segluromet on ravim, mida kasutatakse II tüüpi diabeediga täiskasvanutel vere glükoosisisalduse (veresuhkru) reguleerimiseks.
English: Treatment will not be started if the kidney function is poor.
Estonian: Kui neerufunktsioon on halb, siis ravi ei alustata.
English: How is Segluromet used?
Estonian: Kuidas Seglurometi kasutatakse?
English: For the full list of side effects of Segluromet, see the package leaflet.
Estonian: Seglurometi kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What benefits of Segluromet have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Seglurometi kasulikkus?
English: • The first study found that in patients taking a combination of ertugliflozin and metformin, HbA1c levels fell by around 0.8 points, compared with reductions of 0.03 when placebo (a dummy treatment) was added to metformin.
Estonian: • Esimeses uuringus leiti, et ertugliflosiini ja metformiini kombinatsiooni kasutanud patsientidel vähenes HbA1c sisaldus ligikaudu 0,8 protsendipunkti, samas kui platseebo (näiva ravimi) lisamisel metformiinile vähenes HbA1c sisaldus 0,03 protsendipunkti.
English: • A second study found that adding ertugliflozin to a combination of sitagliptin (another diabetes medicine) and metformin was more effective than placebo.
Estonian: • Teises uuringus leiti, et ertugliflosiini lisamine sitagliptiini (samuti diabeediravim) ja metformiini kombinatsioonile oli efektiivsem kui platseebo lisamine.
English: The doctor will check how well the patient's kidneys are working before treatment and once a year during treatment.
Estonian: Enne ravi alustamist ja ravi ajal üks kord aastas kontrollib arst patsiendi neerude tööd.
English: The two active substances in Segluromet, ertugliflozin and metformin, work in different ways to lower glucose levels.
Estonian: Seglurometi kaks toimeainet, ertugliflosiin ja metformiin, vähendavad vere glükoosisisaldust eri viisil.
English: Finally, in addition to lowering glucose levels, studies showed that adding ertugliflozin to metformin helped patients reduce bodyweight.
Estonian: Uuringud näitasid, et peale vere glükoosisisalduse vähendamise aitas ertugliflosiini lisamine metformiinile patsientidel alandada ka kehakaalu.
English: The dose of Segluromet may be reduced or it may be stopped if the kidneys are not working well enough.
Estonian: Kui neerud ei tööta piisavalt hästi, võib olla vaja Seglurometi annust vähendada või ravi lõpetada.
English: Metformin, on the other hand, works mainly by blocking glucose production in the body and by reducing the absorption of glucose in the gut.
Estonian: Metformiin takistab organismis glükoosi tootmist ja vähendab glükoosi imendumist soolestikust.
English: How does Segluromet work?
Estonian: Kuidas Segluromet toimib?
English: • patients on the highest dose of metformin they can take who are also taking another diabetes medicine
Estonian: • patsiendid, kes kasutavad neile sobivat maksimaalset metformiiniannust ja ka teisi diabeediravimeid;
English: Segluromet can only be obtained with a prescription.
Estonian: Segluromet on retseptiravim.
English: HbA1c levels fell by between 0.8 and 0.9 percentage points when ertugliflozin was added, compared with a fall of 0.1 with placebo
Estonian: Ertugliflosiini lisamisel vähenes HbA1c sisaldus ligikaudu 0,8-0,9 protsendipunkti, samas kui platseebo lisamisel vähenes HbA1c sisaldus 0,1 protsendipunkti.
English: • The fourth study found that, in patients taking metformin, adding ertugliflozin was as effective as adding sitagliptin with HbA1c levels falling by around 1 point with both treatments.
Estonian: • Neljandas uuringus leiti, et metformiini kasutavatel patsientidel oli ertugliflosiini lisamine sama efektiivne nagu sitagliptiini lisamine.
English: Why is Segluromet authorised in the EU?
Estonian: ELis Seglurometile väljastatud müügiloa põhjendus
English: What measures are being taken to ensure the safe and effective use of Uptravi?
Estonian: Mis meetmed võetakse, et tagada Uptravi ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Uptravi on 12 May 2016.
Estonian: Euroopa Komisjon andis Uptravi müügiloa, mis kehtib kogu Euroopa Liidus, 12. mail 2016.
English: The full EPAR for Uptravi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Uptravi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Uptravi is available as tablets (200; 400; 600; 800; 1,000; 1,200; 1,400 and 1,600 micrograms).
Estonian: Uptravit turustatakse tablettidena (200, 400, 600, 800, 1000, 1200, 1400 ja 1600 mikrogrammi).
English: What is Uptravi and what is it used for?
Estonian: Mis on Uptravi ja milleks seda kasutatakse?
English: Patients may tolerate treatment better if they take their tablets with food and take the first tablet of an increased dose in the evening rather than the morning.
Estonian: Patsiendid võivad taluda ravi paremini, kui nad võtavad tablette koos toiduga ja võtavad esimese suurema annuse tableti õhtul, mitte hommikul.
English: The main measure of effectiveness was based on the number of patients whose disease worsened or who died during treatment or shortly after treatment had ended.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kelle haigus süvenes või kes surid ravi ajal või veidi pärast ravi lõppu.
English: These effects are mild or moderate and are most frequently seen while the dose of Uptravi is being increased.
Estonian: Need nähud on kerged või mõõdukad ja esinevad kõige sagedamini Uptravi annuse suurendamise ajal.
English: Other information about Uptravi
Estonian: Muu teave Uptravi kohta
English: Why is Uptravi approved?
Estonian: Miks Uptravi heaks kiideti?
English: Regarding safety, the side effects with Uptravi are considered acceptable.
Estonian: Ohutuse osas peetakse Uptravi kõrvalnähte vastuvõetavateks.
English: It must also not be used in patients who have had a stroke within the last 3 months.
Estonian: Ravimit ei tohi kasutada patsiendid, kellel on viimase 3 kuu jooksul olnud insult.
English: Uptravi selexipag
Estonian: Uptravi seleksipaag
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Uptravi's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Uptravi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: What are the risks associated with Uptravi?
Estonian: Mis riskid Uptraviga kaasnevad?
English: It is not intended to provide practical advice on how to use Uptravi.
Estonian: Hindamisaruandes ei anta Uptravi kasutamise praktilisi nõuandeid.
English: Compared with other medicines in the same class which are given into a vein, Uptravi has the advantage of being given by mouth.
Estonian: Võrreldes sama klassi muude ravimitega, mida manustatakse veeni, on Uptravi eeliseks suukaudne kasutamine.
English: The diary contains boxes for the patient to mark the number and strength of tablets they take each day.
Estonian: Päevikus on lahtrid, kuhu patsient kirjutab iga päev võetud tablettide arvu ja tugevuse.
English: Treatment should be started at a dose of 200 micrograms twice a day, approximately 12 hours apart.
Estonian: Ravi tuleb alustada annusega 200 µg kaks korda ööpäevas, võetuna ligikaudu 12-tunnise vahega.
English: For patients with other heart problems, Uptravi must only be used under close medical supervision.
Estonian: Teiste südameprobleemidega patsiendid tohivad Uptravit kasutada ainult hoolika meditsiinilise jälgimise korral.
English: The dose is then increased weekly, as long as it is tolerated, to a maximum of 1,600 micrograms twice daily, which is then continued afterwards.
Estonian: Seejärel suurendatakse annust üks kord nädalas, olenevalt sellest, kuidas patsient suurendamist talub, kuni maksimaalse annuseni 1600 µg kaks korda ööpäevas, mida seejärel jätkatakse.
English: Overall, 24.4% (140 out of 574) of patients treated with Uptravi either died or showed signs of worsening disease compared with 36.4% (212 out of 582) of patients treated with placebo.
Estonian: Patsiente, kes surid või kellel ilmnesid süveneva haiguse tunnused, oli Uptravi uuringurühmas kokku 24,4% (140 patsienti 574st) ja platseeborühmas 36,4% (212 patsienti 582st).
English: If the patient cannot tolerate an increased dose, the doctor may have to reduce it.
Estonian: Kui patsient suuremat annust ei talu, peab arst annust vähendama.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Uptravi have also been included in the summary of product characteristics and the package leaflet.
Estonian: Uptravi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: If stopping treatment with Uptravi, the dose should be reduced gradually.
Estonian: Uptraviga ravi lõpetamisel tuleb annust vähendada järk-järgult.
English: Although the CHMP noted a small apparent increase in the rate of death for patients taking Uptravi when compared with placebo, they considered that this was due to chance or to the way the study was designed and therefore did not impact the benefits or risks of the medicine.
Estonian: Kuigi inimravimite komitee täheldas Uptravi uuringurühmas patsientide suremuse vähest näilist suurenemist võrreldes platseeborühmaga, oli komitee arvamusel, et see oli juhuslik või toimus uuringu ülesehituse tõttu ega mõjuta ravimi kasulikkuse ja riski tasakaalu.
English: Any prescriber of Uptravi will have to register first with the company that markets Uptravi before being able to prescribe it.
Estonian: Kõik Uptravi määravad arstid peavad enne ravimi määramist end registreerima Uptravit turustavas ettevõttes.
English: The company will provide educational materials for the healthcare professionals who will prescribe and dispense the medicine to help them prescribe the medicine correctly and avoid medication errors.
Estonian: Ettevõte saadab ravimit määravale ja väljastavale tervishoiutöötajale teabematerjalid, mis aitavad tal ravimit patsientidele õigesti määrata ja vältida ravivigu.
English: What benefits of Uptravi have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Uptravi kasulikkus?
English: These materials will also include a guide and diary to be given to patients to help them keep track of the number of tablets to take and explain how doses should be increased.
Estonian: Need materjalid sisaldavad ka patsientide teabematerjali ja päevikut, mis aitab neil jälgida võetud tablettide arvu, samuti selgitatakse, kuidas annust suurendatakse.
English: Patients were given either Uptravi or placebo (a dummy treatment) for around 70 weeks.
Estonian: Patsiendid kasutasid ligikaudu 70 nädala jooksul kas Uptravit või platseebot (näiv ravim).
English: This is a summary of the European public assessment report (EPAR) for Uptravi.
Estonian: See on ravimi Uptravi Euroopa avaliku hindamisaruande kokkuvõte.
English: For the full list of restrictions and side effects reported with Uptravi, see the package leaflet.
Estonian: Uptravi kohta teatatud piirangute ja kõrvalnähtude täielik loetelu on pakendi infolehel.
English: If tolerated, this dose can be increased weekly.
Estonian: Taluvuse korral tohib annust üks kord nädalas suurendada.
English: The most common side effects with Uptravi (which may affect more than 1 in 10 people) are headache, diarrhoea, nausea and vomiting, jaw pain, myalgia (muscle pain), pain in the limbs, arthralgia (joint pain) and flushing.
Estonian: Uptravi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on peavalu, kõhulahtisus, iiveldus ja oksendamine, lõuavalu, lihasevalu, jäsemevalu, liigesevalu ja õhetus.
English: Uptravi contains the active substance selexipag.
Estonian: Uptravi sisaldab toimeainena seleksipaagi.
English: Uptravi must not be used in patients who have had a heart attack within the last 6 months, severe coronary heart disease (heart disease caused by the obstruction of the blood vessels that supply the heart muscle) or unstable angina (a severe type of chest pain).
Estonian: Uptravit ei tohi kasutada patsiendid, kellel on viimase 6 kuu jooksul olnud südamelihase infarkt, kellel on raske pärgarterihaigus (südamelihast verega varustavate veresoonte ummistusest tingitud südamehaigus) või ebastabiilne stenokardia (tugev rindkerevalu).
English: It can be used in combination with other medicines called endothelin receptor antagonists (ERA) or phosphodiesterase type-5 (PDE-5) inhibitors or on its own for patients for whom these medicines are not suitable.
Estonian: Uptravit tohib kasutada koos teatud teiste ravimitega - endoteliiniretseptori antagonistidega (ERA) või 5. tüüpi fosfodiesteraasi (PDE-5) inhibiitoritega - või ainsa ravimina patsientidel, kellele need ravimid ei sobi.